- Home
- COLL vs ECC Comparison
COLL vs ECC Comparison
Compare COLL & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- ECC
- Stock Information
- Founded
- COLL 2002
- ECC N/A
- Country
- COLL United States
- ECC United States
- Employees
- COLL N/A
- ECC N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- ECC
- Sector
- COLL Health Care
- ECC
- Exchange
- COLL Nasdaq
- ECC NYSE
- Market Cap
- COLL 1.1B
- ECC 966.1M
- IPO Year
- COLL 2015
- ECC N/A
- Fundamental
- Price
- COLL $33.35
- ECC $8.85
- Analyst Decision
- COLL Strong Buy
- ECC Buy
- Analyst Count
- COLL 5
- ECC 2
- Target Price
- COLL $43.80
- ECC $11.00
- AVG Volume (30 Days)
- COLL 486.5K
- ECC 679.0K
- Earning Date
- COLL 02-20-2025
- ECC 02-22-2024
- Dividend Yield
- COLL N/A
- ECC 19.16%
- EPS Growth
- COLL 757.11
- ECC 369.44
- EPS
- COLL 2.16
- ECC 1.69
- Revenue
- COLL $599,245,000.00
- ECC $122,654,279.00
- Revenue This Year
- COLL $13.20
- ECC $36.58
- Revenue Next Year
- COLL $17.63
- ECC $12.88
- P/E Ratio
- COLL $15.42
- ECC $5.93
- Revenue Growth
- COLL 9.62
- ECC 96.41
- 52 Week Low
- COLL $28.39
- ECC $8.60
- 52 Week High
- COLL $42.29
- ECC $11.79
- Technical
- Relative Strength Index (RSI)
- COLL 62.31
- ECC 41.07
- Support Level
- COLL $32.29
- ECC $8.83
- Resistance Level
- COLL $33.99
- ECC $8.99
- Average True Range (ATR)
- COLL 1.29
- ECC 0.14
- MACD
- COLL 0.51
- ECC 0.00
- Stochastic Oscillator
- COLL 87.40
- ECC 42.54
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About ECC EAGLE POINT CREDIT CO LLC
Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.